Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7299
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    82.65
    -0.16 (-0.19%)
     

  • Bitcoin CAD

    88,166.44
    -3,121.98 (-3.42%)
     

  • CMC Crypto 200

    1,388.77
    -35.33 (-2.48%)
     

  • GOLD FUTURES

    2,328.10
    -10.30 (-0.44%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,465.00
    -199.50 (-1.13%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    0.00 (0.00%)
     

  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

ChemoCentryx (CCXI) Moves 109.2% Higher: Will This Strength Last?

Zacks Equity Research
·2 min read

ChemoCentryx (CCXI) shares rallied 109.2% in the last trading session to close at $50.43. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 4.8% loss over the past four weeks.

The stock rallied driven by optimism over the agreement under which Amgen agreed to acquire ChemoCentryx for approximately $3.7 billion in cash.

This biopharmaceutical company is expected to post quarterly loss of $0.51 per share in its upcoming report, which represents a year-over-year change of +8.9%. Revenues are expected to be $12.79 million, up 606.6% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

ADVERTISEMENT

For ChemoCentryx, the consensus EPS estimate for the quarter has been revised marginally higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on CCXI going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

ChemoCentryx belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Marinus Pharmaceuticals (MRNS), closed the last trading session 2% higher at $5.49. Over the past month, MRNS has returned 12.8%.

Marinus Pharmaceuticals' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.93. Compared to the company's year-ago EPS, this represents a change of -43.1%. Marinus Pharmaceuticals currently boasts a Zacks Rank of #3 (Hold).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ChemoCentryx, Inc. (CCXI) : Free Stock Analysis Report
 
Marinus Pharmaceuticals, Inc. (MRNS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.